World’s 20 most attractive biopharmaceutical employers for 2016, according to Science magazine
In a new analysis by the Science magazine, Regeneron Pharmaceuticals was found to be world’s most attractive biopharmaceutical company worldwide. The top three companies in the list – Regeneron Pharmaceuticals, Novo Nordisk, and Moderna Therapeutics.
Eli Lilly and Company ranked No. 4 among biotechnology and pharmaceutical companies worldwide. The survey features the 20 best companies in the biotechnology, biopharmaceutical, pharmaceutical and related industries.
The survey, which lists the top 20 employers, noting its performance in areas such as financial strength, easy adaptation to change and a research-driven environment.
So which biotechnology and pharmaceutical companies made Science magazine’s global top 20?
1. Regeneron Pharmaceuticals (Tarrytown, NY)
2. Novo Nordisk (Bagsvaerd, Denmark)
3. Moderna Therapeutics (Cambridge, MA)
4. Eli Lilly and Company (Indianapolis, IN)
5. Vertex Pharmaceuticals (Boston, MA)
6. Novozymes (Bagsvaerd, Denmark)
7. Genentech (South San Francisco, CA)
8. Alexion Pharmaceuticals (New Haven, CT)
9. Biocon (Bangalore, India)
10. Roche—excluding Genentech (Basel, Switzerland)
11. Merck KGaA (Darmstadt, Germany)
12. AbbVie (North Chicago, IL)
13. Monsanto Company (Creve Coeur, MO)
14. Syngenta (Basel, Switzerland)
15. Abbott (Abbott Park, IL)
16. Boehringer Ingelheim (Ingelheim, Germany)
17. Celgene Corporation (Summit, NJ)
18. Bayer (Leverkusen, Germany)
19. Novartis (Basel, Switzerland)
20. Johnson & Johnson (New Brunswick, NJ)
Add CEOWORLD magazine to your Google News feed.
Follow CEOWORLD magazine headlines on: Google News, LinkedIn, Twitter, and Facebook.
This report/news/ranking/statistics has been prepared only for general guidance on matters of interest and does not constitute professional advice. You should not act upon the information contained in this publication without obtaining specific professional advice. No representation or warranty (express or implied) is given as to the accuracy or completeness of the information contained in this publication, and, to the extent permitted by law, CEOWORLD magazine does not accept or assume any liability, responsibility or duty of care for any consequences of you or anyone else acting, or refraining to act, in reliance on the information contained in this publication or for any decision based on it.
Copyright 2024 The CEOWORLD magazine. All rights reserved. This material (and any extract from it) must not be copied, redistributed or placed on any website, without CEOWORLD magazine' prior written consent. For media queries, please contact: info@ceoworld.biz
SUBSCRIBE NEWSLETTER